keytruda

Digital Marketing

Week ending August 19, 2026

1. Content opportunities this week

  1. Keytruda administration instructions — Answer: “How is Keytruda administered—IV infusion time, required dilution/infusion rate guidance, and any premedication or flush instructions?” Six responses vary from 357–490 words and inconsistently address handling details, creating a clear need for one label-based administration guide.

  2. AST/ALT dose modification thresholds — Answer: “If my labs show elevated AST/ALT after Keytruda, what labeled actions are recommended (hold dose vs permanently discontinue), and at what thresholds?” Responses are relatively short (207–311 words) and provide partial threshold tables; a definitive hold/resume/discontinue chart would be highly citable.

  3. Eligibility, contraindications, and high-risk situations — Answer: “Who is not eligible for Keytruda—are there any contraindications or situations where it should be avoided (e.g., prior organ transplant, active autoimmune disease)?” All six answers use cautionary language, with inconsistent coverage of infection risk, autoimmune disease, transplant history, pregnancy, and hypersensitivity.

  4. Biosimilar and substitution explainer — Answer: “At the pharmacy, they asked if I want Keytruda specifically or can substitute something else—does substitution happen for Keytruda, and why/why not?” and the related generic/biosimilar question generated 12 responses and 13 biosimilar/generic tags. The answers repeatedly hedge around country, payer, and interchangeability rules—an opportunity for a clearly segmented, jurisdiction-specific resource.

2. Where competitors may be winning visibility

No competitor mentions were recorded in the responses (competitor_mentions: []). Although Opdivo and Tecentriq appear in the questions, the data does not show them being cited inside answers about Keytruda. Therefore, no competitor-specific visibility gap can be established this week.

3. Topics worth resolving with authoritative content

  • Administration instructions: Resolve inconsistent inclusion of “do not use”/contraindication language while covering IV-only administration, 30-minute infusion, dilution, rate, preparation, premedication, and line-flush requirements.
  • Warfarin and interaction guidance: Answer “I’m on warfarin and starting Keytruda—are there labeled drug–drug interaction concerns with anticoagulants or CYP/P-gp substrates?” A definitive piece should distinguish absence of a labeled CYP/P-gp interaction from practical anticoagulation monitoring considerations.
  • Eligibility and infection risk: Clarify the difference between a formal contraindication and situations requiring caution, including prior transplant, active autoimmune disease, infection risk, pregnancy, and hypersensitivity.

4. Prioritization — recurring vs. one-off

This is a baseline week: no prior week is available and the trend history contains only 2026-08-19. No topic can yet be classified as recurring or growing. All 10 questions appeared this week with six responses each, so prioritize by information gap and clinical usefulness, then reassess recurrence next week.

5. Recommended content actions

  1. Publish a label-based “Keytruda administration and infusion instructions” page answering the exact administration question; prioritize because of six responses and cross-response inconsistency.
  2. Create an AST/ALT management table covering CTCAE ranges, when to continue or hold, restart criteria, and permanent discontinuation thresholds; prioritize because answers are short and incomplete.
  3. Create an eligibility and contraindications guide separating absolute contraindications from cautionary situations; address the inconsistent infection-risk coverage.
  4. Publish a regional biosimilar/substitution FAQ answering both exact pharmacy and generic/biosimilar questions, with separate U.S./EU/local-rule sections.
  5. Add a warfarin/CYP/P-gp interaction FAQ grounded in current prescribing information and monitoring considerations.